Baxter's Allegiance first quarter sales increased by 1% to $1.12 bil. -- SEC filing.
This article was originally published in The Gray Sheet
Executive Summary
BAXTER'S ALLEGIANCE SALES INCREASED 1% IN FIRST QUARTER 1996 to $1.12 bil., up from $1.11 bil. in the same period of 1995, the firm says in a Securities and Exchange Commission filing. The slim increase was the result of "planned attempts to reduce sales growth and improve profitability in lower margin, distributed products in the U.S.," the document says. The figures, which exclude the impact of divested businesses, are the first divulged by Baxter for Allegiance, its hospital-supply subsidiary scheduled to be spun off this September under a plan announced in November 1995 ("The Gray Sheet" Dec. 4, 1995, p. 3).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.